Merck Sues Watson Labs To Block Generic Contraceptive

Law360, New York (June 5, 2013, 1:14 PM EDT) -- Merck & Cie and Bayer Pharma AG on Tuesday accused generic-drug maker Watson Laboratories Inc. of infringing the patent for their contraceptive Safyral by seeking approval for a generic version of the drug, according to identical suits filed in federal courts in Delaware and Nevada.

Switzerland-based Merck, which owns the patent for Safyral, and Bayer, the patent's exclusive licensee, asked the court for a permanent injunction barring Watson from manufacturing or selling its generic and preventing the U.S. Food and Drug Administration from approving it before...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.